What is the appropriate brand name (with generic name) for single‑inhaler triple therapy and what is the comprehensive management plan?

Single-Inhaler Triple Therapy for COPD: Brand Names and Comprehensive Management Plan

For patients with moderate to severe COPD at high risk of exacerbations (≥2 moderate or ≥1 severe exacerbation in the past year) with significant symptoms (CAT ≥10, mMRC ≥2) and FEV1 <80% predicted, initiate single-inhaler triple therapy (SITT) with LAMA/LABA/ICS, preferably using one of the following brand names:

Available Brand Names for Single-Inhaler Triple Therapy

Primary Options:

• Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) - once daily DPI
• Trimbow/Breztri (beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide) - twice daily extrafine pMDI or DPI (NEXThaler)
• Breyna (budesonide/glycopyrrolate/formoterol) - twice daily pMDI
• Enerzair Breezhaler (mometasone furoate/indacaterol/glycopyrronium) - once daily DPI

1, 2, 3

Comprehensive Management Algorithm

Step 1: Patient Stratification

Assess three key parameters:

1. Symptom burden: Use CAT score (≥10 = high symptoms) or mMRC scale (≥2 = high symptoms)
2. Exacerbation risk: Count moderate exacerbations (requiring antibiotics/oral steroids) and severe exacerbations (requiring hospitalization/ED visit) in past 12 months
3. Lung function: Measure post-bronchodilator FEV1 (% predicted)

1

Step 2: Treatment Selection Based on Risk Profile

High-Risk Patients (Triple Therapy Indicated):

• ≥2 moderate exacerbations OR ≥1 severe exacerbation in past year
• AND CAT ≥10 or mMRC ≥2
• AND FEV1 <80% predicted

Critical evidence: Triple therapy reduces mortality compared to LAMA/LABA dual therapy in this population—this is the most important outcome-based recommendation from the 2023 CTS guideline 1. The ETHOS trial demonstrated statistically significant reduction in all-cause mortality with triple therapy, with independent adjudication confirming lower rates of respiratory and cardiovascular death.

Moderate-Risk Patients (Dual Therapy):

• ≤1 moderate exacerbation in past year
• AND symptomatic (CAT ≥10 or mMRC ≥2)
• Use LAMA/LABA dual therapy (not triple therapy)

1

Step 3: Device Selection

Choose device based on patient's inspiratory capacity and coordination:

• Poor inspiratory flow (<30 L/min) or coordination issues: Trimbow pMDI (breath-actuated, less flow-dependent) 2
• Good inspiratory capacity, prefers once-daily: Trelegy Ellipta 2, 4
• Requires high lung deposition, can manage twice-daily: Trimbow NEXThaler (∼55% lung deposition) 2
• Technique-sensitive patients: Breyna Aerosphere (most robust to inhalation variations) 2

Step 4: Monitoring and Optimization

At 3 months:

• Reassess CAT score (expect ≥3-4 point reduction) 5
• Check inhaler technique
• Measure adherence
• Count exacerbations since initiation

At 6 months:

• Measure FEV1 (expect ≥100 mL improvement in >40% of patients) 5
• Reassess symptoms and quality of life
• Evaluate exacerbation frequency

At 12 months:

• Full reassessment of all parameters
• Consider step-down ONLY if: patient at low exacerbation risk, stable symptoms, and specifically requests de-escalation due to concerns about ICS adverse effects 1

5

Step 5: Critical Safety Monitoring

Monitor for pneumonia risk:

• Fluticasone furoate-containing products (Trelegy) carry substantially increased pneumonia risk 6
• Beclometasone (Trimbow) and budesonide (Breyna) formulations show lower pneumonia rates 6
• Consider beclometasone or budesonide-based SITT in patients with prior pneumonia history

Other adverse effects to monitor:

• Oral candidiasis (all ICS-containing products)
• Cardiovascular effects (monitor in patients with cardiac comorbidities)
• Bone density (long-term ICS use)

7, 6

Special Populations

Asthma-COPD Overlap:

• Triple therapy strongly indicated regardless of exacerbation history
• ICS component is essential (not optional)

1, 8

Eosinophilic COPD (blood eosinophils >300 cells/μL):

• Enhanced response to ICS component
• Triple therapy preferred even with lower exacerbation frequency

6

Non-eosinophilic, infrequent exacerbators:

• May safely use LAMA/LABA dual therapy instead
• Avoid unnecessary ICS exposure and pneumonia risk

6

Common Pitfalls to Avoid

1. Do not use ICS/LABA dual therapy when triple therapy is indicated—LAMA/LABA dual therapy is superior to ICS/LABA for most COPD patients due to better lung function and lower pneumonia rates 1

2. Do not prescribe multiple separate inhalers when SITT is available—single-inhaler formulations improve adherence and reduce technique errors 1

3. Do not step down from triple therapy in high-risk patients who are stable—withdrawal may worsen health status and lung function 1

4. Do not ignore device-patient matching—wrong device selection leads to poor technique and treatment failure 2

5. Do not continue triple therapy indefinitely without reassessment in patients who were never at high exacerbation risk—these patients may benefit from de-escalation to LAMA/LABA 6